Steven Kelly

Vice President

Steve has over 20 years of experience working in health technology assessment, evidence-based medicine, health economics, and pricing and market access within the pharmaceutical industry.

Prior to joining CRA, Steve was Senior Director for Global Health & Value at Pfizer responsible for global market access of hospital products in Pfizer’s established products business. His expertise has focused on pricing and market access in Europe, with in-depth experience of health technology assessment (HTA) in the UK. He has worked on a broad range of therapeutic areas throughout the lifecycle from Phase 2 to post loss of exclusivity.

Selected Engagements

  • 01
    Evaluating the potential impact of cross-border healthcare for gene therapies
    Issue Our client sought to understand the current state of healthcare across borders (also known as medical tourism) and the opportunities and risks this...
    View engagement
  • 02
    Global pricing and access strategic issues assessment for rare diseases gene therapy portfolio
    Issue Our client is developing gene therapies for different rare disease indications, some with effective treatments available and others with only symptom...
    View engagement